<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002244953
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Avysk
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Avysk<sup>&reg; </sup></strong>contains the active substance: valsartan and belongs to a class of medicines known as angiotensin II receptor antagonists, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. <strong>Avysk<sup>&reg; </sup></strong>works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p><strong>&nbsp;</strong></p><p><strong>Avysk<sup>&reg; </sup>can be used for three different conditions: </strong></p><p>To treat high blood pressure in adult and in children and adolescents 6 to less than 18 years of age.<strong> </strong>High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p>To treat adult patients after a recent heart attack<strong> </strong>(myocardial infarction)<strong>. </strong>&ldquo;Recent&rdquo; here means between 12 hours and 10 days.</p><p>To treat symptomatic heart failure in adult patients.<strong> Avysk<sup>&reg; </sup></strong>is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE-inhibitors when other medications to treat heart failure cannot be used. Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Avysk<sup>&reg;</sup>: </strong></p><p>If you are allergic<strong> </strong>(hypersensitive) to valsartan or any of the other ingredients of this medicine.</p><p>If you have severe liver disease.<strong> </strong></p><p>If you are more than 3 months pregnant<strong> </strong>(it is also better to avoid <strong>Avysk<sup>&reg; </sup></strong>in early pregnancy).</p><p>If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>If any of the above apply to you, tell your doctor and do not take <strong>Avysk<sup>&reg; </sup></strong>.</p><p><strong>Warnings and precautions</strong></p><p><strong>Talk to your doctor: </strong></p><p>If you have liver disease.</p><p>If you have severe kidney disease or if you are undergoing dialysis.</p><p>If you are suffering from a narrowing of the kidney artery.</p><p>If you have recently undergone kidney transplantation (received a new kidney).</p><p>If you have severe heart disease other than heart failure or heart attack.</p><p>If you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug (including ACE inhibitors), tell your doctor. If these symptoms occur when you are taking <strong>Avysk<sup>&reg;</sup></strong>, stop taking <strong>Avysk<sup>&reg; </sup></strong>immediately and never take it again.</p><p>If you are taking medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.</p><p>If you suffer from aldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of <strong>Avysk<sup>&reg; </sup></strong>is not recommended.</p><p>If you have lost a lot of fluid (dehydration) caused by diarrhea, vomiting, or high doses of water tablets (diuretics).</p><p>If you are taking any of the following medicines used to treat high blood pressure:</p><p>- An ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>- Aliskiren.</p><p>- if you are being treated with an ACE inhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid receptors antagonists (MRA) (for example spironolactone, eplerenone) or betablockers (for example metoprolol).</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>You must tell your doctor if you think you are <u>(or might become) </u>pregnant. <strong>Avysk<sup>&reg; </sup></strong>is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage.</p><p><strong>Other medicines and Avysk<sup>&reg;</sup></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.</p><p>The effect of the treatment can be influenced if <strong>Avysk<sup>&reg; </sup></strong>is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This applies to both prescription and non-prescription medicines, especially:</p><p>Other medicines that lower blood pressure, especially water tablets<strong> </strong>(diuretics), ACE inhibitors (such as enalapril, lisinopril, etc.,) or aliskiren.</p><p>Medicines that increase the amount of potassium<strong> </strong>in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>Certain type of pain killers called non-steroidal anti-inflammatory medicines (NSAIDs).</p><p>Some antibiotics (rifamycin group), a drug used to protect against transplant rejection (ciclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (ritonavir). These drugs may increase the effect of <strong>Avysk<sup>&reg;</sup></strong>.</p><p>Lithium, a medicine used to treat some types of psychiatric illness.</p><p><strong>In addition: </strong></p><p>If you are being treated after a heart attack, a combination with ACE inhibitors (a medication to treat heart attack) is not recommended.</p><p>If you are being treated for heart failure, a triple combination with ACE inhibitors and other medicines to treat your heart failure which are known as mineralocorticoid receptors antagonists (MRA) (for example spironolactone, epleronone) or beta blockers (for example metoprolol) is not recommended.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>You must tell your doctor if you think that you are (<u>or might become</u>) pregnant. Your doctor will normally advise you to stop taking <strong>Avysk<sup>&reg; </sup></strong>before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of <strong>Avysk<sup>&reg;</sup></strong>. <strong>Avysk<sup>&reg; </sup></strong>is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding.<strong> Avysk<sup>&reg; </sup></strong>is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>Driving and using machines </strong></p><p>Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how <strong>Avysk<sup>&reg; </sup></strong>affects you. Like many other medicines used to treat high blood pressure, <strong>Avysk<sup>&reg; </sup></strong>may cause dizziness and affect the ability to concentrate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you in order to get the best results and reduce the risk of side effects. Check with your doctor or pharmacist if you are not sure. People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with the doctor even if you are feeling well.</p><p><strong>Adult patients with high blood pressure:</strong></p><p>The recommended dose is 80 mg daily. In some cases your doctor may prescribe higher doses (e.g. <strong>Avysk<sup>&reg; </sup></strong>160 mg or valsartan 320 mg). He may also combine <strong>Avysk<sup>&reg;</sup></strong> with an additional medicine (e.g. a diuretic).</p><p><strong>Children and adolescents 6 to less than 18 years of age with high blood pressure: </strong></p><p>In patients who weigh less than 35 kg the recommended starting dose for valsartan is 40 mg once daily.</p><p>In patients who weigh 35 kg or more the recommended starting dose for <strong>Avysk<sup>&reg; </sup></strong>tablet is 80 mg once daily.</p><p>In some cases your doctor may prescribe higher doses (the dose can be increased to <strong>Avysk<sup>&reg; </sup></strong>160 mg and to a maximum of valsartan 320 mg).</p><p>For children who are unable to swallow tablets, the use of the valsartan<strong><sup> </sup></strong>oral solution is recommended.</p><p><strong>Adult patients after a recent heart attack:</strong></p><p>After a heart attack the treatment is generally started as early as after 12 hours, usually at a low dose of 20 mg twice daily. Your doctor will increase this dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate.</p><p><strong>Avysk<sup>&reg; </sup></strong>can be given together with other treatment for heart attack, and your doctor will decide which treatment is suitable for you.</p><p><strong>Adult patients with heart failure: </strong></p><p>Treatment starts generally with 40 mg twice daily. Your doctor will increase the dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate.</p><p><strong>Avysk<sup>&reg; </sup></strong>can be given together with other treatment for heart failure, and your doctor will decide which treatment is suitable for you.</p><p>You can take <strong>Avysk<sup>&reg; </sup></strong>with or without food. Swallow <strong>Avysk<sup>&reg; </sup></strong>with a glass of water.</p><p>Take <strong>Avysk<sup>&reg; </sup></strong>at about the same time each day.</p><p><strong>If you take more Avysk<sup>&reg; </sup>than you should </strong></p><p>If you experience severe dizziness and/or fainting, contact your doctor immediately and lie down. If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital.</p><p><strong>If you forget to take Avysk<sup>&reg;</sup></strong></p><p>If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Avysk<sup>&reg;</sup></strong></p><p>Stopping your treatment with <strong>Avysk<sup>&reg; </sup></strong>may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.&nbsp;</p><p>If you have further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Some side effects can be serious and need immediate medical attention: </strong></p><p>You may experience symptoms of angioedema (a specific allergic reaction), such as:</p><p>Swollen face, lips, tongue or throat.</p><p>Difficulty in breathing or swallowing.</p><p>Hives, itching.</p><p><strong>If you get any of these symptoms, stop taking Avysk<sup>&reg; </sup>and contact your doctor straight away. </strong></p><p><strong>Other side effects include: </strong></p><p><strong>Common (may affect up to 1 in 10 people): </strong></p><p>Dizziness.</p><p>Low blood pressure with or without symptoms such as dizziness and fainting when standing up.</p><p>Decreased kidney function (signs of renal impairment).</p><p><strong>Uncommon (may affect up to 1 in 100 people): </strong></p><p>Angioedema.</p><p>Sudden loss of consciousness (syncope).</p><p>Spinning sensation (vertigo).</p><p>Severely decreased kidney function (signs of acute renal failure).</p><p>Muscle spasms, abnormal heart rhythm (signs of hyperkalaemia).</p><p>Breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of cardiac failure).</p><p>Headache.</p><p>Cough.</p><p>Abdominal pain.</p><p>Nausea.</p><p>Diarrhea.</p><p>Tiredness.</p><p>Weakness.</p><p><strong>Not known (frequency cannot be estimated from the available data): </strong></p><p>Blistering skin (sign of dermatitis bullous).</p><p>Allergic reactions with rash, itching and hives; symptoms of fever, swollen joints and joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms may occur (signs of serum sickness).</p><p>Purplish-red spots, fever, itching (signs of inflammation of blood vessels also called vasculitis).</p><p>Unusual bleeding or bruising (signs of thrombocytopenia).</p><p>Muscle pain (myalgia).</p><p>Fever, sore throat or mouth ulcers due to infections (symptoms of low level of white blood cells also called neutropenia).</p><p>Decrease of level of haemoglobin and decrease of the percentage of red blood cells in the blood (which can lead to anaemia in severe cases).</p><p>Increase of level of potassium in the blood (which can trigger muscle spasms and abnormal heart rhythm in severe cases).</p><p>Elevation of liver function values (which can indicate liver damage) including an increase of bilirubin in the blood (which can trigger yellow skin and eyes in severe cases).</p><p>Increase of level of blood urea nitrogen and increase of level of serum creatinine (which can indicate abnormal kidney function).</p><p>Low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases).</p><p>The frequency of some side effects may vary depending on your condition. For example, side effects such as dizziness, and decreased kidney function, were seen less frequently in adult patients treated with high blood pressure than in adult patients treated for heart failure or after a recent heart attack.</p><p>Side effects in children and adolescents are similar to those seen in adults.</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Avysk<sup>&reg;</sup> </strong>tablets after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Avysk<sup>&reg;</sup> </strong>tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Valsartan.&nbsp;</p><p>The other ingredients are microcrystalline cellulose, croscarmellose sodium, povidone K30, anhydrous colloidal silica, magnesium stearate, Opadry II White (lactose monohydrate, HPMC, titanium dioxide, macrogol), FD&amp;C red #40.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Avysk® 80 mg tablets: are pink color round biconvex film coated tablets engraved with H27 on one side and scored on the other side, presented in Alu/Alu blisters, intended for oral use.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Pack size: 30 film coated tablets (10 tablets/ blister, 3 blisters/pack).
Avysk® 160 mg tablets: are pink color round biconvex film coated tablets engraved with H25 on one side and plain on the other side, presented in Alu/Alu blister, intended for oral use.
Pack size: 30 film coated tablets(10 tablets/ blister, 3 blisters/pack).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Med City Pharma-KSA.</strong></p><p>1st Industrial city, Phase 5, Jeddah &ndash;KSA.</p><p>Tel: 00966920003288</p><p>Mobile: 00966555786968</p><p>P.O .Box: 4072 - Jeddah 22429</p><p>E-mail: info@medcitypharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                08/2024    
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>على المادة الفعالة: ڤالسارتان و ينتمي إلى مجموعة من الأدوية تعرف بمضادات مستقبلات أنجيوتنسين II، التي تساعد في السيطرة على ضغط الدم المرتفع. تصنع مادة أنجيوتنسين II في الجسم التي تسبب انقباض الأوعية الدموية، وهذا يسبب ارتفاع ضغط الدم.</p><p dir="RTL">يعمل <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> على حصر تأثير أنجيوتنسين II. وبالتالي ينتج عن ذلك استرخاء الأوعية الدموية وانخفاض ضغط الدم.</p><p dir="RTL"><strong>من</strong><strong> </strong><strong>الممكن</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>الثلاث</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">لعلاج ارتفاع ضغط الدم عند البالغين و الأطفال و المراهقين الذين تبلغ أعمارهم 6 أعوام إلى أقل من 18 عام.</p><p dir="RTL">يزيد ارتفاع ضغط الدم العبء على القلب والشرايين. إذا لم يتم علاجه من الممكن أن يسبب تلف الأوعية الدموية في الدماغ، القلب، والكلى، وقد يسبب السكتة الدماغية، قصور وظيفة عضلة القلب، أو الكلى. يزيد ارتفاع ضغط الدم من خطر الإصابة بالنوبة القلبية. إن تخفيض ضغط الدم إلى المستوى الطبيعي يقلل خطر الإصابة بهذه الاضطرابات.&nbsp;</p><p dir="RTL">لعلاج المرضى البالغين الذين أصيبوا مؤخرا بنوبة قلبية (احتشاء عضلة القلب). &ldquo;مؤخرا&rdquo; تعني في هذه الحالة بين 12 ساعة و 10 أيام.</p><p dir="RTL">لعلاج أعراض قصور وظيفة عضلة القلب عند المرضى البالغين. يستعمل <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>عندما لا يمكن استعمال مجموعة من الأدوية تعرف بمثبطات الإنزيم المحول للأنجيوتنسين (أدوية لعلاج قصور وظيفة عضلة القلب)، أو من الممكن استعماله بالإضافة إلى مثبطات الإنزيم المحول للأنجيوتنسين عندما لا يمكن استعمال أدوية أخرى لعلاج قصور وظيفة عضلة القلب. تتضمن أعراض قصور وظيفة عضلة القلب قصر النفس، تورم القدمين والساقين نتيجة تجمع السوائل. وينتج ذلك عندما لا تستطيع عضلة القلب ضخ الدم بقوة كافية لتزويد الجسم بما يحتاجه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong> <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من تحسس (فرط التحسس) لڤالسارتان أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">إذا كنت تعاني من مرض حاد في الكبد.</p><p dir="RTL">إذا كنت حامل لمدة تزيد عن 3 أشهر (من الأفضل أيضا تجنب تناول <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>في المرحلة المبكرة من الحمل).</p><p dir="RTL">إذا كنت تعاني من داء السكري أو قصور وظيفة الكلى ويتم علاجك باستعمال دواء خافض لضغط الدم يحتوي&nbsp; على أليسكيرين.</p><p dir="RTL">إذا كان أي مما ذكر في الأعلى ينطبق عليك، أخبر طبيبك و تجنب تناول<strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>الإحتياطات</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المحاذير</strong></p><p dir="RTL"><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من مرض في الكبد.</p><p dir="RTL">إذا كنت تعاني من مرض حاد في الكلى أو إذا كنت تخضع للديلزة الدموية.</p><p dir="RTL">إذا كنت تعاني من تضيق في الشريان الكلوي.</p><p dir="RTL">إذا خضعت مؤخرا لعملية زرع الكلى (زرع كلى جديدة).</p><p dir="RTL">إذا كنت تعاني من مرض حاد في القلب غير قصور وظيفة عضلة القلب أو النوبة القلبية.</p><p dir="RTL">إذا عانيت سابقا من تورم في اللسان و الوجه نتيجة تفاعل تحسسي يعرف بالوذمة الوعائية عند تناول دواء آخر (بما في ذلك مثبطات الإنزيم المحول للأنجيوتنسين)، أخبر طبيبك. إذا حدثت هذه الأعراض عند تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong>، توقف عن تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> مباشرة ولا تتناوله مرة أخرى.</p><p dir="RTL">إذا كنت تتناول أدوية تزيد من كمية البوتاسيوم في الدم. هذا يتضمن مكملات البوتاسيوم أو الأملاح البديلة المحتوية على البوتاسيوم، الأدوية الحافظة للبوتاسيوم وهيبارين. قد يكون من الضروري التأكد من كمية البوتاسيوم في الدم خلال فترات منتظمة.</p><p dir="RTL">إذا كنت تعاني من ألدوستيرونية. وهو عبارة عن مرض تفرز فيه الغدة الكظرية كمية كبيرة من هرمون&nbsp; الألدوستيرون. إذا كان هذا ينطبق عليك، لا يوصى باستعمال <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا فقدت كمية كبيرة من السوائل (جفاف) نتيجة لإسهال، قيء، أو جرعات عالية من أقراص الماء (مدرات البول).</p><p dir="RTL">إذا كنت تتناول أي من الأدوية التالية التي تستعمل لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">- مثبطات الإنزيم المحول للأنجيوتنسين (مثل إنالابريل، ليزينوبريل، راميبريل)، خصوصا إذا كنت تعاني من أمراض الكلى الناتجة عن داء السكري.</p><p dir="RTL">- أليسكيرين.</p><p dir="RTL">- إذا كان يتم علاجك بمثبطات الإنزيم المحول للأنجيوتنسين مع بعض الأدوية الأخرى لعلاج قصور وظيفة عضلة القلب، والتي تعرف باسم مضادات مستقبلات القشرانيات المعدنية (على سبيل المثال سبيرونولاكتون، إبليرينون) أو حاصرات بيتا (على سبيل المثال ميتوبرولول).</p><p dir="RTL">قد يقوم طبيبك بالتحقق من وظيفة الكلى، ضغط الدم، و كمية الكهرليات (مثلا، البوتاسيوم) في الدم خلال فترات منتظمة.</p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت تعتقدين بأنك (أو قد تصبحين) حامل. لا يوصى باستعمال <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>في المرحلة المبكرة من الحمل، و يجب عدم تناوله إذا كنت حامل لمدة تزيد عن 3 أشهر، وذلك لأنه قد يسبب أذى خطير على الجنين إذا تم استعماله في هذه المرحلة.</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>و</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا، أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL">قد يتأثر مفعول العلاج إذا تم تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> بالتزامن مع أدوية أخرى. قد يكون من الضروري تغيير الجرعة، لاتخاذ احتياطات أخرى، أو في حالات أخرى التوقف عن تناول أحد الأدوية الأخرى. وهذا ينطبق على كل من الأدوية التي يتم تناولها بوصفة طبية أو بدون وصفة طبية، خصوصا:</p><p dir="RTL">الأدوية الأخرى الخافضة لضغط الدم<strong>،</strong> خصوصا أقراص الماء (مدرات البول)، مثبطات الإنزيم المحول للأنجيوتنسين (مثل إنالابريل، ليزينوبريل، إلخ) أو أليسكيرين.</p><p dir="RTL">الأدوية التي تزيد كمية البوتاسيوم في الدم. هذا يتضمن مكملات البوتاسيوم أو الأملاح البديلة المحتوية على البوتاسيوم، الأدوية الحافظة للبوتاسيوم وهيبارين.</p><p dir="RTL">أدوية معينة مسكنة للألم تعرف بالأدوية غير الستيرويدية المضادة للالتهاب.</p><p dir="RTL">بعض المضادات الحيوية (مجموعة ريفامايسين)، دواء يستعمل للوقاية من رفض العضو المزروع (سيكلوسبورين) أو دواء مضاد للڤيروسات الذي يستعمل لعلاج ڤيروس نقص المناعة المكتسبة/الإيدز (ريتوناڤير). قد تزيد هذه الأدوية من تأثير <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong>.&nbsp;</p><p dir="RTL">ليثيوم، دواء يستعمل لعلاج بعض أنواع الأمراض النفسية.</p><p dir="RTL"><strong>بالإضافة</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>ذلك</strong><strong>:</strong></p><p dir="RTL">&nbsp;إذا كنت تخضع لعلاج بعد إصابتك بنوبة قلبية، لا يوصى باستعماله بالتزامن مع مثبطات الإنزيم المحول للأنجيوتنسين (دواء لعلاج النوبة القلبية).</p><p dir="RTL">إذا كنت تخضع لعلاج قصور وظيفة عضلة القلب، لا يوصى باستعماله بالتزامن مع كل من مثبطات الإنزيم المحول للأنجيوتنسين وأدوية أخرى لعلاج قصور وظيفة عضلة القلب التي تعرف باسم مضادات مستقبلات القشرانيات المعدنية (على سبيل المثال سبيرونولاكتون، إبليرينون) أو حاصرات بيتا (على سبيل المثال ميتوبرولول).</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت تعتقدين بأنك حامل (أو من الممكن حصول الحمل). سينصحك الطبيب عادة بالتوقف عن تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> قبل حصول الحمل أو في حال التأكد من حصوله، وسينصحك بتناول دواء آخر بدلا من <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">لا يوصى باستعمال <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>في المرحلة المبكرة من الحمل،<strong><sup> </sup></strong>ويجب عدم تناوله إذا كنت حاملا لمدة تزيد عن 3 أشهر حيث قد يسبب هذا أذى خطير على الجنين إذا تم استعماله بعد الشهر الثالث من الحمل.</p><p dir="RTL">أخبر الطبيب إذا كنت مرضعة أو على وشك البدء بالرضاعة الطبيعية. لا يوصى باستعمال <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> للأمهات المرضعات، وقد يختار الطبيب علاج آخر لك إذا كنت ترغبين في الرضاعة الطبيعية، خصوصا إذا كان طفلك حديث الولادة، أو ولد قبل أوانه.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>و</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>الآلات</strong><strong> </strong></p><p dir="RTL">قبل قيادة المركبة، استعمال أدوات أو تشغيل الآلات، أو القيام بنشاطات تحتاج التركيز، تأكد من معرفة كيفية تأثير <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>عليك. كما هو الحال مع العديد من الأدوية الأخرى التي تم استعمالها لعلاج ارتفاع ضغط الدم، قد يسبب <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>الشعور بالدوار و يؤثر على قدرتك على التركيز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما أخبرك طبيبك للحصول على أفضل النتائج وتقليل خطر الإصابة بالآثار الجانبية. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا. إن الأشخاص الذين يعانون من ارتفاع ضغط الدم غالبا لا يلاحظون أي علامات لهذه المشكلة. العديد قد يشعرون بوضع طبيعي. هذا يجعل من الضروري أكثر الالتزام بمواعيد الطبيب حتى إذا كنت تشعر بتحسن.</p><p dir="RTL"><strong>المرضى</strong><strong> </strong><strong>البالغون</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>يعانون</strong><strong> </strong><strong>من</strong><strong> </strong><strong>ارتفاع</strong><strong> </strong><strong>ضغط</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><p dir="RTL">الجرعة الموصى بها هي 80 ملغم يوميا. في بعض الحالات قد يصف الطبيب جرعة أعلى (مثل <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>160 ملغم أو ڤالسارتان 320 ملغم). قد يصف أيضا بالتزامن مع <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> دواء إضافي (مثل مدر للبول).</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المراهقون</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>تبلغ</strong><strong> </strong><strong>أعمارهم</strong><strong> 6 </strong><strong>أعوام</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 18 </strong><strong>عام</strong><strong> </strong><strong>و</strong><strong> </strong><strong>يعانون</strong><strong> </strong><strong>من</strong><strong> </strong><strong>ارتفاع</strong><strong> </strong><strong>ضغط</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><p dir="RTL">المرضى الذين تبلغ أوزانهم أقل من 35 كغم الجرعة الابتدائية الموصى بها من ڤالسارتان هي 40 ملغم مرة واحدة يوميا.</p><p dir="RTL">المرضى الذين تبلغ أوزانهم 35 كغم أو أكثر الجرعة الابتدائية الموصى بها من <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> هي 80 ملغم مرة واحدة يوميا.</p><p dir="RTL">في بعض الحالات قد يصف الطبيب جرعة أعلى (مثل <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>160 ملغم إلى الجرعة القصوى من ڤالسارتان 320 ملغم).</p><p dir="RTL">يوصى باستعمال ڤالسارتان محلول عن طريق الفم للأطفال غير القادرين على تناول الأقراص.</p><p dir="RTL"><strong>المرضى</strong><strong> </strong><strong>البالغون</strong> <strong>بعد</strong><strong> </strong><strong>الإصابة</strong><strong> </strong><strong>مؤخرا</strong><strong> </strong><strong>بنوبة</strong><strong> </strong><strong>قلبية</strong><strong>:</strong></p><p dir="RTL">بعد الإصابة بنوبة قلبية يبدأ العلاج بشكل عام في أقرب وقت بعد 12 ساعة، عادة بجرعة منخفضة تبلغ 20 ملغم مرتين يوميا. سيقوم الطبيب بزيادة هذه الجرعة بالتدريج خلال عدة أسابيع لتصل إلى أعلى جرعة 160 ملغم مرتين يوميا. تعتمد الجرعة النهائية على مدى تحملك.</p><p dir="RTL">من الممكن إعطاء <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> بالتزامن مع علاج آخر لعلاج النوبة القلبية، وسيقرر الطبيب ما هو العلاج المناسب لك.</p><p dir="RTL"><strong>المرضى</strong><strong> </strong><strong>البالغون</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>يعانون</strong><strong> </strong><strong>من</strong><strong> </strong><strong>قصور</strong><strong> </strong><strong>وظيفة</strong><strong> </strong><strong>عضلة</strong><strong> </strong><strong>القلب</strong><strong>:</strong></p><p dir="RTL">يبدأ العلاج بشكل عام بجرعة 40 ملغم مرتين يوميا. سيقوم الطبيب بزيادة الجرعة بالتدريج خلال عدة أسابيع لتصل إلى أعلى جرعة 160 ملغم مرتين يوميا. تعتمد الجرعة النهائية على مدى تحملك.</p><p dir="RTL">من الممكن إعطاء <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> بالتزامن مع علاج آخر لعلاج قصور وظيفة القلب، وسيقرر الطبيب ما هو العلاج المناسب لك.</p><p dir="RTL">من الممكن تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> مع أو بدون تناول الطعام. قم بتناول <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>مع شرب كوب من الماء.</p><p dir="RTL">تناول <strong>أڤيسك</strong><strong><sup>&reg; </sup></strong>تقريبا في نفس الوقت من كل يوم.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>قمت</strong><strong> </strong><strong>بتناول</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong><strong> </strong></p><p dir="RTL">إذا عانيت من الشعور بالدوار الحاد و/أو الإغماء، قم بالاستلقاء واتصل مع طبيبك فورا.</p><p dir="RTL">إذا تناولت عن طريق الخطأ عدد كبير من الأقراص، اتصل مع طبيبك، الصيدلي، أو المستشفى.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناولها حال تذكرك. لكن، إذا اقترب موعد الجرعة التالية، تجاوز عن الجرعة التي نسيتها.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">إن التوقف عن العلاج باستعمال <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong> قد يسبب ازدياد المرض سوءا. لا تتوقف عن تناول دوائك ما لم يخبرك الطبيب بذلك.</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء في آثار جانبية، على الرغم من عدم حصولها لدى الجميع.</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>بعض</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>خطيرة</strong><strong> </strong><strong>و</strong><strong> </strong><strong>تحتاج</strong><strong> </strong><strong>لعناية</strong><strong> </strong><strong>طبية</strong><strong> </strong><strong>فورية</strong><strong>:</strong></p><p dir="RTL">قد تعاني من أعراض الوذمة الوعائية (تفاعل تحسسي معين)، مثل:</p><p dir="RTL">تورم الوجه، الشفاه، اللسان أو الحلق.</p><p dir="RTL">صعوبة في التنفس أو البلع.</p><p dir="RTL">الشرى، حكة.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأعراض،</strong><strong> </strong><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>واتصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فورا</strong><strong>.</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>تتضمن</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">الشعور بالدوار.</p><p dir="RTL">انخفاض ضغط الدم مع&nbsp; أو بدون ظهور أعراض مثل الشعور بالدوار و الإغماء عند الوقوف.</p><p dir="RTL">قصور وظيفة الكلى.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">وذمة وعائية.</p><p dir="RTL">فقدان مفاجئ للوعي.</p><p dir="RTL">شعور بالدوران.</p><p dir="RTL">قصور حاد في وظيفة الكلى (علامات قصور وظيفة الكلى المزمن).</p><p dir="RTL">تشنج عضلي، عدم انتظام نبضات القلب (علامات ارتفاع مستوى البوتاسيوم في الدم).</p><p dir="RTL">عدم القدرة على التنفس، صعوبة في التنفس عند الاستلقاء، تورم القدمين أو الساقين (علامات قصور وظيفة عضلة القلب).</p><p dir="RTL">صداع.</p><p dir="RTL">سعال</p><p dir="RTL">ألم بطني.</p><p dir="RTL">الشعور بالغثيان.</p><p dir="RTL">إسهال.</p><p dir="RTL">شعور بالتعب.</p><p dir="RTL">شعور بالضعف.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>):</strong></p><p dir="RTL">تنفط الجلد (علامات التهاب الجلد الفقاعي).</p><p dir="RTL">تفاعلات تحسسية يصاحبها طفح، حكة و شرى، مع ظهور الأعراض التالية: حمى، تورم المفاصل و ألم في المفاصل، تورم العقد الليمفاوية و/أو أعراض تشبه الإنفلونزا (علامات مرض المصل).</p><p dir="RTL">بقع حمراء بنفسجية، حمى، حكة (علامات التهاب الأوعية الدموية).</p><p dir="RTL">نزيف غير طبيعي أو كدمات (علامات قلة الصفيحات).</p><p dir="RTL">ألم العضلات.</p><p dir="RTL">حمى، تقرحات في الحلق أو الفم نتيجة التهابات (أعراض انخفاض مستوى خلايا الدم البيضاء المعروفة أيضا بقلة العدلات).</p><p dir="RTL">انخفاض مستوى الهيموغلوبين و نسبة خلايا الدم الحمراء في الدم (الذي قد يسبب في حالات حادة الإصابة بفقر الدم).</p><p dir="RTL">ارتفاع مستوى البوتاسيوم في الدم (الذي قد يسبب في حالات حادة، تحفيز تشنج العضلات، اضطراب نظمية القلب).</p><p dir="RTL">ارتفاع قيم نتائج فحوصات وظائف الكبد (الذي قد يشير إلى حدوث تلف في الكبد) بما في ذلك ارتفاع مستوى البيليروبين في الدم (الذي قد يسبب في حالات حادة، تحفيز اصفرار الجلد والعيون).</p><p dir="RTL">ارتفاع مستوى يوريا نيتروجين في الدم و الكرياتينين في المصل (الذي قد يشير إلى حدوث قصور في وظيفة الكلى).</p><p dir="RTL">انخفاض مستوى الصوديوم في الدم (الذي قد يحفز الشعور بالتعب، الارتباك، نفضان العضلات و/أو التشنجات في الحالات الحادة).</p><p dir="RTL">إن تكرار بعض الآثار الجانبية قد يختلف اعتمادا على حالتك. مثلا، آثار جانبية مثل الشعور بالدوار، وقصور وظيفة الكلى، لوحظ تكرارها أقل عند المرضى البالغين الذين عولجوا وكانوا يعانون من ارتفاع ضغط الدم من أولئك المرضى البالغين الذين عولجوا وكانوا يعانون من قصور وظيفة عضلة القلب أو بعد الإصابة بنوبة قلبية مؤخرا.</p><p dir="RTL">الآثار الجانبية عند الأطفال و المراهقين تشبه الآثار الجانبية عند البالغين.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية،</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>. </strong><strong>بما</strong><strong> </strong><strong>في</strong><strong> </strong><strong>ذلك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>محتملة</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل<strong> </strong>أقراص <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong>بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong>&nbsp; </strong>أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي: ڤالسارتان.</p><p dir="RTL">المكونات الأخرى هي: ميكروكريستالين سيليلوز، كروسكارميللوز صوديوم، بوفيدون 30K، سيليكا غروية لا مائية، ستيرات المغنيسيوم، أوبادري II أبيض (لاكتوز أحادي الهيدرات، هيدروكسي بروبيل ميثيل سيليلوز، ثاني أكسيد التيتانيوم، ماكروجول)، لون أحمر FD &amp; C رقم 04.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أڤيسكا</strong><strong><sup>&reg; </sup></strong><strong>80 </strong><strong>ملغم</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>مغلفة</strong><strong>: </strong>أقراص مغلفة<strong> </strong>دائرية الشكل، ذات لون وردي، محدبة الوجهين محفور H27 على احد الأوجه و خط التقسيم على الوجه الأخر، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL">إن خط التقسيم هو فقط لتسهيل عملية تقسيم القرص لتسهيل البلع وليس لتقسيم القرص إلى جرعات متساوية.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 30 قرص مغلف (10 أقراص/شريط، 3 أشرطة/ علبة).</p><p dir="RTL"><strong>أڤيسك</strong><strong><sup>&reg; </sup></strong><strong>160 </strong><strong>ملغم</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>مغلفة</strong><strong>: </strong>أقراص مغلفة<strong> </strong>دائرية الشكل، ذات لون وردي، محدبة الوجهين محفور H25 على أحد الأوجه، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 30 قرص مغلف (10 أقراص/شريط، 3 أشرطة/ علبة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية.</p><p dir="RTL">المدينة الصناعية الأولى، المرحلة الخامسة، جدة - المملكة العربية السعودية.</p><p dir="RTL">هاتف: 00966920003288</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 4072 - جدة 22429</p><p dir="RTL">بريد الكتروني: info@medcitypharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            08/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Avysk® 80 mg Film Coated Tablets.
Avysk® 160 mg Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Avysk® 80 mg: Each film coated tablet contains 80 mg valsartan.
Avysk® 1600 mg: Each film coated tablet contains 160 mg valsartan.

For a full list of excipients: see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablets.

Avysk® 80 mg tablets: are pink color round biconvex film coated tablets engraved with H27 on one side and scored on the other side, presented in Alu/Alu blisters, intended for oral use.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Avysk® 160 mg tablets: are pink color round biconvex film coated tablets engraved with H25 on one side and plain on the other side, presented in Alu/Alu blister, intended for oral use.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypertension </u></p><p>Treatment of essential hypertension in adults, and hypertension in children and adolescents 6 to less than 18 years of age.</p><p><u>Recent myocardial infarction </u></p><p>Treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours-10 days) myocardial infarction (see sections 4.4 and 5.1).</p><p><u>Heart failure </u></p><p>Treatment of adult patients with symptomatic heart failure when Angiotensin Converting Enzyme (ACE) inhibitors are not tolerated or in beta-blocker intolerant patients as add-on therapy to ACE inhibitors when mineralocorticoid receptor antagonists cannot be used (see sections 4.2, 4.4, 4.5 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Posology </u></em></p><p><u>Hypertension </u></p><p>The recommended starting dose of <strong>Avysk<sup>&reg; </sup></strong>is 80 mg once daily. The antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg.</p><p><strong>Avysk<sup>&reg; </sup></strong>may also be administered with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1). The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.</p><p><u>Recent myocardial infarction </u></p><p>In clinically stable patients, therapy may be initiated as early as 12 hours after a myocardial infarction. After an initial dose of 20 mg twice daily, valsartan should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40 mg divisible.</p><p>The target maximum dose is 160 mg twice daily. In general, it is recommended that patients achieve a dose level of 80 mg twice daily by two weeks after treatment initiation and that the target maximum dose, 160 mg twice daily, be achieved by three months, based on the patient&#39;s tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dose reduction.</p><p>Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins, and diuretics. The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1).</p><p>Evaluation of post-myocardial infarction patients should always include assessment of renal function.</p><p><u>Heart failure </u></p><p>The recommended starting dose of valsartan is 40 mg twice daily. Up titration to 80 mg and 160 mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses.</p><p>Valsartan may be administered with other heart failure therapies. However, the triple combination of an ACE inhibitor, valsartan and a beta blocker or a potassium-sparing diuretic is not recommended (see sections 4.4 and 5.1).</p><p>Evaluation of patients with heart failure should always include assessment of renal function.</p><p><em><u>Additional information on special populations </u></em></p><p><u>Older people </u></p><p>No dose adjustment is required in elderly patients.</p><p><u>Patients with Renal impairment </u></p><p>No dose adjustment is required for adult patients with a creatinine clearance &gt;10 ml/min (see sections 4.4 and 5.2).</p><p><u>Patients with Hepatic impairment </u></p><p><strong>Avysk<sup>&reg; </sup></strong>is contraindicated in patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). In patients with mild to moderate hepatic impairment without cholestasis, the dose of valsartan should not exceed 80 mg.</p><p><em><u>Paediatric population </u></em></p><p><u>Paediatric hypertension </u></p><p>For children and adolescents who are unable to swallow tablets, the use of the valsartan oral solution is recommended. The systemic exposure and peak plasma concentration of valsartan is about 1.7-fold and 2.2-fold higher with the solution compared to the tablets.</p><p><em><u>Children and adolescents 6 to less than 18 years of age </u></em></p><p>For valsartan tablets, the initial dose is 40 mg once daily for children weighing below 35 kg and 80 mg once daily for those weighing 35 kg or more. The dose should be adjusted based on blood pressure response and tolerability. For maximum doses studied in clinical trials please refer to the table below.</p><p>Doses higher than those listed have not been studied and are therefore not recommended.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum dose of tablet studied in clinical trials</p></td></tr><tr><td style="vertical-align:top"><p>&ge;18 kg to &lt;35 kg</p></td><td style="vertical-align:top"><p>80 mg</p></td></tr><tr><td style="vertical-align:top"><p>&ge;35 kg to &lt;80 kg</p></td><td style="vertical-align:top"><p>160 mg</p></td></tr><tr><td style="vertical-align:top"><p>&ge;80 kg to &le;160 kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>320 mg</p></td></tr></tbody></table><p>For children already started on valsartan prior to the age of six years, please refer to the posology for valsartan oral solution (Children 1 to less than 6 years of age).</p><p><em><u>Children less than 6 years of age </u></em></p><p>For children aged 1 to 5 years and for those having difficulties in swallowing the tablet, valsartan oral solution is recommended. Available data are described in sections 4.8, 5.1 and 5.2. The safety and efficacy of valsartan in children below 1 year of age have not been established.</p><p><em><u>Switching from valsartan oral solution to valsartan tablets </u></em></p><p>If switching from valsartan oral solution to valsartan tablets is considered clinically essential, initially the same dose in milligrams should be given. Subsequently, frequent blood pressure monitoring should be performed taking into account potential under-dosing and the dose should be titrated further based on blood pressure response and tolerability.</p><p><em><u>Use in paediatric patients aged 6 to less than 18 years with renal impairment </u></em></p><p>Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.4 and 5.2).</p><p><em><u>Use in paediatric patients aged 6 to less than 18 years with hepatic impairment </u></em></p><p>As in adults, <strong>Avysk<sup>&reg; </sup></strong>is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). There is limited clinical experience with valsartan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80 mg in these patients.</p><p><em><u>Paediatric heart failure and recent myocardial infarction </u></em></p><p><strong>Avysk<sup>&reg; </sup></strong>is not recommended for the treatment of heart failure or recent myocardial infarction in children and adolescents below the age of 18 years due to the lack of data on safety and efficacy.</p><p><em><u>Method of administration </u></em></p><p><strong>Avysk<sup>&reg; </sup></strong>may be taken independently of a meal and should be administered with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
-Severe hepatic impairment, biliary cirrhosis and cholestasis. 
-Second and third trimester of pregnancy (see sections 4.4 and 4.6). 
-Concomitant use of Avysk® with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hyperkalaemia </u></p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p><u>Impaired renal function </u></p><p>There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients. No dose adjustment is required for adult patients with creatinine clearance &gt;10 ml/min (see sections 4.2 and 5.2).</p><p><u>Hepatic impairment </u></p><p>In patients with mild to moderate hepatic impairment without cholestasis, <strong>Avysk<sup>&reg; </sup></strong>should be used with caution (see sections 4.2 and 5.2).</p><p><u>Sodium- and/or volume-depleted patients </u></p><p>In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with <strong>Avysk<sup>&reg;</sup></strong>. Sodium and/or volume depletion should be corrected before starting treatment with <strong>Avysk<sup>&reg;</sup></strong>, for example by reducing the diuretic dose.</p><p><u>Renal artery stenosis </u></p><p>In patients with bilateral renal artery stenosis or stenosis to a solitary kidney, the safe use of <strong>Avysk<sup>&reg; </sup></strong>has not been established.</p><p>Short-term administration of <strong>Avysk<sup>&reg; </sup></strong>to twelve patients with renovascular hypertension secondary to unilateral renal artery stenosis did not induce any significant changes in renal haemodynamics, serum creatinine, or blood urea nitrogen (BUN). However, other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal artery stenosis, therefore monitoring of renal function is recommended when patients are treated with valsartan.</p><p><u>Kidney transplantation </u></p><p>There is currently no experience on the safe use of <strong>Avysk<sup>&reg; </sup></strong>in patients who have recently undergone kidney transplantation.</p><p><u>Primary hyperaldosteronism </u></p><p>Patients with primary hyperaldosteronism should not be treated with <strong>Avysk<sup>&reg; </sup></strong>as their renin-angiotensin system is not activated.</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy </u></p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p><u>Pregnancy </u></p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be</p><p><u>Hyperkalaemia </u></p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p><u>Impaired renal function </u></p><p>There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients. No dose adjustment is required for adult patients with creatinine clearance &gt;10 ml/min (see sections 4.2 and 5.2).</p><p><u>Hepatic impairment </u></p><p>In patients with mild to moderate hepatic impairment without cholestasis, <strong>Avysk<sup>&reg; </sup></strong>should be used with caution (see sections 4.2 and 5.2).</p><p><u>Sodium- and/or volume-depleted patients </u></p><p>In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with valsartan. Sodium and/or volume depletion should be corrected before starting treatment with <strong>Avysk<sup>&reg;</sup></strong>, for example by reducing the diuretic dose.</p><p><u>Renal artery stenosis </u></p><p>In patients with bilateral renal artery stenosis or stenosis to a solitary kidney, the safe use of valsartan has not been established.</p><p>Short-term administration of valsartan to twelve patients with renovascular hypertension secondary to unilateral renal artery stenosis did not induce any significant changes in renal haemodynamics, serum creatinine, or blood urea nitrogen (BUN). However, other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal artery stenosis, therefore monitoring of renal function is recommended when patients are treated with valsartan.</p><p><u>Kidney transplantation </u></p><p>There is currently no experience on the safe use of valsartan in patients who have recently undergone kidney transplantation.</p><p><u>Primary hyperaldosteronism </u></p><p>Patients with primary hyperaldosteronism should not be treated with <strong>Avysk<sup>&reg; </sup></strong>as their renin-angiotensin system is not activated.</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy </u></p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p><u>Pregnancy </u></p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be</p><p>There is evidence that the concomitant use of ACE inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia, and decreased renal function (including acute renal failure). Dual blockade of the RAAS through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em><u>Paediatric population </u></em></p><p><u>Impaired renal function </u></p><p>Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min (see sections 4.2 and 5.2). Renal function and serum potassium should be closely monitored during treatment with valsartan. This applies particularly when valsartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function.</p><p><u>Impaired hepatic function </u></p><p>As in adults, <strong>Avysk<sup>&reg; </sup></strong>is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3 and 5.2). There is limited clinical experience with valsartan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80 mg in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) with ARBs, ACEIs, or aliskiren </u></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><em><u>Concomitant use not recommended </u></em></p><p><em>Lithium </em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists including with valsartan. If the combination proves necessary, a careful monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may presumably be increased further.</p><p><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels </em></p><p>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p><em><u>Caution required with concomitant use </u></em></p><p><em>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid &gt;3 g/day), and non-selective NSAIDs </em></p><p>When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p><em><u>Transporters </u></em>In vitro data indicates that valsartan is a substrate of the hepatic uptake transporter OATP1B1/OATP1B3 and the hepatic efflux transporter MRP2. The clinical relevance of this finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin, ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to valsartan. Exercise appropriate care when initiating or ending concomitant treatment with such drugs.</p><p><em>Others </em></p><p>In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide.</p><p><em><u>Paediatric population </u></em></p><p>In hypertension in children and adolescents, where underlying renal abnormalities are common, caution is recommended with the concomitant use of valsartan and other substances that inhibit the renin angiotensin aldosterone system which may increase serum potassium. Renal function and serum potassium should be closely monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:0;margin-top:28.9pt;width:437.25pt;height:49.5pt;z-index:251661312;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:left;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-align:justify'><span style='font-family:
    "Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:
    minor-bidi;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi'>The
    use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended
    during the first trimester of pregnancy (see section 4.4). The use of
    AIIRAs is contra-indicated during the second and third trimester of
    pregnancy (see sections 4.3 and 4.4).<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="margin"/>
</v:shape><![endif]--></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:0;margin-top:28.9pt;width:437.25pt;height:49.5pt;z-index:251661312;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:left;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='text-align:justify'><span style='font-family:
    "Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-hansi-theme-font:
    minor-bidi;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi'>The
    use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended
    during the first trimester of pregnancy (see section 4.4). The use of
    AIIRAs is contra-indicated during the second and third trimester of
    pregnancy (see sections 4.3 and 4.4).<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="margin"/>
</v:shape><![endif]--><img width="587" height="70" alt="Text Box: The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4)." src="file:///C:/Users/BASMAH~1.ALR/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><strong>4.6 Fertility, pregnancy and lactation</strong></p><p>The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p><u>Pregnancy</u></p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia); see also section 5.3 &ldquo;Preclinical safety data&rdquo;.</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><em><u>Breast-feeding </u></em></p><p>Because no information is available regarding the use of valsartan during breastfeeding, <strong>Avysk<sup>&reg; </sup></strong>is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><em><u>Fertility </u></em></p><p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m<sup>2 </sup>basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive have been performed. When driving vehicles or operating machines it should be taken into account that dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In controlled clinical studies in adult patients with hypertension, the overall incidence of adverse drug reactions (ADRs) was comparable with placebo and is consistent with the pharmacology of valsartan. The incidence of ADRs did not appear to be related to dose or treatment duration and also showed no association with gender, age or race.</p><p>The ADRs reported from clinical studies, post-marketing experience and laboratory findings are listed below according to system organ class.</p><p><strong><u>Adverse Drug Reactions </u></strong></p><p>Adverse drug reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000) very rare (&lt; 1/10,000), not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse drug reactions are ranked in order of decreasing seriousness.</p><p>For all the ADRs reported from post-marketing experience and laboratory findings, it is not possible to apply any ADR frequency and therefore they are mentioned with a &quot;not known&quot; frequency.</p><p>- <u>Hypertension</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Decrease in haemoglobin, Decrease in haematocrit, Neutropenia,</p><p>Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Increase of serum potassium, hyponatraemia</p></td></tr></tbody></table></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepato-biliary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevation of liver function values including increase of serum bilirubin</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema, Dermatitis bullous, Rash, Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure and impairment, Elevation of serum creatinine</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr></tbody></table><p><em><u>Paediatric population </u></em></p><p><u>Hypertension </u></p><p>The antihypertensive effect of valsartan has been evaluated in two randomised, double-blind clinical studies (each followed by an extension period or study) and one open-label study. These studies included 711 paediatric patients from 6 to less than 18 years of age with and without chronic kidney disease (CKD), of which 560 patients received valsartan. With the exception of isolated gastrointestinal disorders (such as abdominal pain, nausea, vomiting) and dizziness, no relevant differences in terms of type, frequency and severity of adverse reactions were identified between the safety profile for paediatric patients aged 6 to less than 18 years and that previously reported for adult patients.</p><p>Neurocognitive and developmental assessment of paediatric patients aged 6 to 16 years of age revealed no overall clinically relevant adverse impact after treatment with valsartan for up to one year.</p><p>A pooled analysis of 560 paediatric hypertensive patients (aged 6-17 years) receiving either valsartan monotherapy [n=483] or combination antihypertensive therapy including valsartan [n=77] was conducted. Of the 560 patients, 85 (15.2%) had CKD (baseline GFR &lt;90 mL/min/1.73m<sup>2</sup>). Overall, 45 (8.0%) patients discontinued a study due to adverse events. Overall 111 (19.8%) patients experienced an adverse drug reaction (ADR), with headache (5.4%), dizziness (2.3%), and hyperkalaemia (2.3%) being the most frequent. In patients with CKD, the most frequent ADRs were hyperkalaemia (12.9%), headache (7.1%), blood creatinine increased (5.9%), and hypotension (4.7%). In patients without CKD, the most frequent ADRs were headache (5.1%) and dizziness (2.7%). ADRs were observed more frequently in patients receiving valsartan in combination with other antihypertensive medications than valsartan alone.</p><p>The antihypertensive effect of valsartan in children 1 to less than 6 years of age has been evaluated in three randomised, double-blind clinical studies (each followed by an extension period). In the first study in 90 children aged 1 to less than 6 years, two deaths and isolated cases of marked liver transaminases elevations were observed. These cases occurred in a population who had significant comorbidities. A causal relationship to valsartan has not been established. In the two subsequent studies in which 202 children aged 1 to less than 6 years were randomised, no significant liver transaminase elevations or death occurred with valsartan treatment.</p><p>In a pooled analysis of the two subsequent studies in 202 hypertensive children (aged 1 to less than 6 years), all patients received valsartan monotherapy in the double blind periods (excluding the placebo withdrawal period). Of these, 186 patients continued in either extension study or open label period. Of the 202 patients, 33 (16.3%) had CKD (baseline eGFR &lt;90 ml/min). In the double blind period, two patients (1%) discontinued due to an adverse event and in the open label or extension period four patients (2.1%) discontinued due to an adverse event. In the double blind period, 13 (7.0%) patients experienced at least one ADR. The most frequent ADRs were vomiting n=3 (1.6%) and diarrhea n=2 (1.1%). There was one ADR (diarrhoea) in the CKD group. In the open label period, 5.4% patients (10/186) had at least one ADR. The most frequent ADR was decreased appetite which was reported by two patients (1.1%). In both the double blind period and the open label periods, hyperkalaemia was reported for one patient in each period. There were no cases of hypotension or dizziness in either double blind or open label periods.</p><p>Hyperkalaemia was more frequently observed in children and adolescents aged 1 to less than 18 years with underlying chronic kidney disease (CKD). The risk of hyperkalaemia may be higher in children aged 1 to 5 years compared to children aged 6 to less than 18 years.</p><p>The safety profile seen in controlled-clinical studies in adult patients with post-myocardial infarction and/or heart failure varies from the overall safety profile seen in hypertensive patients. This may relate to the patients underlying disease. ADRs that occurred in adult patients with post-myocardial infarction and/or heart failure patients are listed below.</p><p>- <u>Post-myocardial infarction and/or heart failure (studied in adult patients only)</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatraemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness, Postural dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, Headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cardiac failure</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension, Orthostatic hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea, Diarrhea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepato-biliary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Angioedema,</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Dermatitis bullous, Rash, Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal failure and impairment</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acute renal failure, Elevation of serum creatinine</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase in Blood Urea Nitrogen</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Asthenia, Fatigue</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull;Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p><strong>&bull;Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms </strong></p><p>Overdose with <strong>Velseva<sup>&reg; </sup></strong>may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock.</p><p><strong>&nbsp;</strong></p><p><strong>Treatment </strong></p><p>The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms; stabilisation of the circulatory condition is of prime importance.</p><p>If hypotension occurs, the patient should be placed in a supine position and blood volume correction should be undertaken.</p><p>Valsartan is unlikely to be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC code: C09CA03</p><p>Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor, which appears to counterbalance the effect of the AT1 receptor. Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000 fold) greater affinity for the AT1 receptor than for the AT2 receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Valsartan does not inhibit ACE (also known as kininase II) which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (p&lt;0.05) less in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry</p><p>cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (p&lt;0.05).</p><p><strong><u>Hypertension</u></strong></p><p>Administration of <strong>Avysk<sup>&reg; </sup></strong>to patients with hypertension results in reduction of blood pressure without affecting pulse rate.</p><p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks and persist during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.</p><p>Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events.</p><p>In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 micrograms/min; amlodipine: 55.4 micrograms/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 micromols/l). At 24 weeks, UAE was reduced (p&lt;0.001) by 42% (&ndash;24.2 micrograms/min; 95% CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3% (&ndash;1.7 micrograms/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups.</p><p>The valasrtan Reduction of Proteinuria study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 micrograms/min; 20-700 micrograms/min) and preserved renal function (mean serum creatinine = 80 micromols/l). Patients were randomized to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI: 22 to 47%), and by 44% with valsartan 320 mg (95%CI: 31 to 54%). It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p><strong><u>Recent myocardial infarction</u></strong></p><p>The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction &le;40% by radionuclide ventriculography or &le;35% by echocardiography or ventricular contrast angiography). Patients were randomised within 12 hours to 10 days after the onset of myocardial infarction symptoms to valsartan, captopril, or the combination of both. The mean treatment duration was two years. The primary endpoint was time to all-cause mortality.</p><p>Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction. All-cause mortality was similar in the valsartan (19.9%), captopril (19.5%), and valsartan + captopril (19.3%) groups. Combining valsartan with captopril did not add further benefit over captopril alone. There was no difference between valsartan and captopril in all-cause mortality based on age, gender, race, baseline therapies or underlying disease. Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint).</p><p>The safety profile of valsartan was consistent with the clinical course of patients treated in the post-myocardial infarction setting. Regarding renal function, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients, 4.8% of valsartan+captopril-treated patients, and 3.4% of captopril-treated patients. Discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients, 1.3% in valsartan+captopril patients, and 0.8% of captopril patients. An assessment of renal function should be included in the evaluation of patients post-myocardial infarction.</p><p>There was no difference in all-cause mortality, cardiovascular mortality or morbidity when beta blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone. Irrespective of treatment, mortality was lower in the group of patients treated with a beta blocker, suggesting that the known beta blocker benefit in this population was maintained in this trial.</p><p><strong><u>Heart failure</u></strong></p><p>Val-HeFT was a randomised, controlled, multinational clinical trial of valsartan compared with placebo on morbidity and mortality in 5,010 NYHA class II (62%), III (36%) and IV (2%) heart failure patients receiving usual therapy with LVEF &lt;40% and left ventricular internal diastolic diameter (LVIDD) &gt;2.9 cm/m2. Baseline therapy included ACE inhibitors (93%), diuretics (86%), digoxin (67%) and beta blockers (36%). The mean duration of follow-up was nearly two years. The mean daily dose of valsartan in Val-HeFT was 254 mg. The study had two primary endpoints: all cause mortality (time to death) and composite mortality and heart failure morbidity (time to first morbid event) defined as death, sudden death with resuscitation, hospitalisation for heart failure, or administration of intravenous inotropic or vasodilator agents for four hours or more without hospitalisation.</p><p>All cause mortality was similar (p=NS) in the valsartan (19.7%) and placebo (19.4%) groups. The primary benefit was a 27.5% (95% CI: 17 to 37%) reduction in risk for time to first heart failure hospitalisation (13.9% vs. 18.5%). Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs. 25.4% in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.</p><p>In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest. In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33% (95% CI: &ndash;6% to 58%) (17.3% valsartan vs. 27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% valsartan vs. 42.5% placebo).</p><p>In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8%) and placebo (22.5%) groups. Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI: 8% to 28%) with valsartan compared with placebo (31.0% vs. 36.3%).</p><p>In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo. Patients treated with valsartan had a better quality of life as demonstrated by change in the Minnesota Living with Heart Failure Quality of Life score from baseline at endpoint than placebo. Ejection fraction in valsartan treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.</p><p><strong><u>Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></strong></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and angiotensin II receptor blockers.</p><p>ACE inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><em><u>Paediatric population</u></em></p><p><u>Hypertension</u></p><p>The antihypertensive effect of valsartan have been evaluated in four randomized, double-blind clinical studies in 561 paediatric patients from 6 to less than 18 years of age and 165 paediatric patients 1 to 6 years of age. Renal and urinary disorders, and obesity were the most common underlying medical conditions potentially contributing to hypertension in the children enrolled in these studies.</p><p><em><u>Clinical experience in children at or above 6 years of age</u></em></p><p>In a clinical study involving 261 hypertensive paediatric patients 6 to 16 years of age, patients who weighed &lt;35 kg received 10, 40 or 80 mg of valsartan daily (low, medium and high doses), and patients who weighed &ge;35 kg received 20, 80, and 160 mg of valsartan daily (low, medium and high doses). At the end of 2 weeks, valsartan reduced both systolic and diastolic blood pressure in a dose-dependent manner. Overall, the three dose levels of valsartan (low, medium and high) significantly reduced systolic blood pressure by 8, 10, 12 mm Hg from the baseline, respectively. Patients were re-randomized to either continue receiving the same dose of valsartan or were switched to placebo. In patients who continued to receive the medium and high doses of valsartan, systolic blood pressure at trough was -4 and -7 mm Hg lower than patients who received the placebo treatment. In patients receiving the low dose of valsartan, systolic blood pressure at trough was similar to that of patients who received the placebo treatment. Overall, the dose-dependent antihypertensive effect of valsartan was consistent across all the demographic subgroups.</p><p>In a second clinical study involving 300 hypertensive paediatric patients 6 to less than 18 years of age, eligible patients were randomized to receive valsartan or enalapril tablets for 12 weeks. Children weighing between &ge;18 kg and &lt;35 kg received valsartan 80 mg or enalapril 10 mg; those between &ge;35 kg and &lt;80 kg received valsartan 160 mg or enalapril 20 mg; those &ge;80 kg received valsartan 320 mg or enalapril 40 mg. Reductions in systolic blood pressure were comparable in patients receiving valsartan (15 mmHg) and enalapril (14 mm Hg) (non-inferiority p-value &lt;0.0001). Consistent results were observed for diastolic blood pressure with reductions of 9.1 mmHg and 8.5 mmHg with valsartan and enalapril, respectively.</p><p>In a third, open label clinical study, involving 150 paediatric hypertensive patients 6 to 17 years of age, eligible patients (systolic BP &ge;95th percentile for age, gender and height) received valsartan for 18 months to evaluate safety and tolerability. Out of the 150 patients participating in this study, 41 patients also received concomitant antihypertensive medication. Patients were dosed based on their weight categories for starting and maintenance doses. Patients weighing &gt;18 to &lt; 35 kg, &ge;35 to &lt; 80 kg and &ge; 80 to &lt; 160 kg received 40 mg, 80 mg and 160 mg and the doses were titrated to 80 mg, 160 mg and 320 mg respectively after one week. One half of the patients enrolled (50.0%, n=75) had CKD with 29.3% (44) of patients having CKD Stage 2 (GFR 60 &ndash; 89 mL/min/1.73m2) or Stage 3 (GFR 30-59 mL/min/1.73m2). Mean reductions in systolic blood pressure were 14.9 mmHg in all patients (baseline 133.5 mmHg), 18.4 mmHg in patients with CKD (baseline 131.9 mmHg) and 11.5 mmHg in patients without CKD (baseline 135.1 mmHg). The percentage of patients who achieved overall BP control (both systolic and diastolic BP &lt;95th percentile) was slightly higher in the CKD group (79.5%) compared to the non-CKD group (72.2%).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Clinical experience in children less than 6 years of age</u></em></p><p>Three clinical studies were conducted in 291 patients aged 1 to 5 years. No children below the age of 1 year were enrolled in these studies.</p><p>In the first study, of 90 patients, dose-response could not be demonstratedbut inthe second study of 75 patients, higher doses of valsartan were associated with greater blood pressure reductions.</p><p>The third study was a 6 week, randomised double-blind study to evaluate the dose response of valsartan in 126 children aged 1 to 5 years with hypertension, with or without CKD randomised to either 0.25 mg/kg or 4 mg/kg body weight. At endpoint, the reduction in Mean systolic blood pressure (MSBP)/ Mean diastolic blood pressure (MDBP) with valsartan 4.0 mg/kg compared to valsartan 0.25 mg/kg was 8.5/6.8 mmHg and 4.1/0.3 mmHg, respectively; (p=0.0157/p&lt;0.0001). Similarly the CKD subgroup also showed reductions in MSBP/MDBP with valsartan 4.0 mg/kg compared to 0.25 mg/kg (9.2/6.5 mmHg vs 1.2/ +1.3 mmHg.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with valsartan in all subsets of the paediatric population in heart failure and heart failure after recent myocardial infarction. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption:</u></em></p><p>Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours with tablets and 1-2 hours with solution formulation. Mean absolute bioavailability is 23% and 39% with tablets and solution formulation, respectively. The systemic exposure and peak plasma concentration of valsartan is about 1.7-fold and 2.2-fold higher with the solution compared to the tablets.</p><p>Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p><em><u>Distribution:</u></em></p><p>The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94&ndash;97%), mainly serum albumin.</p><p><em><u>Biotransformation:</u></em></p><p>Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p><em><u>Elimination:</u></em></p><p>Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated by biliary excretion in faeces (about 83% of dose) and renally in urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p><u>In heart failure patients:</u></p><p>The average time to peak concentration and elimination half-life of valsartan in heart failure patients are similar to that observed in healthy volunteers. AUC and Cmax values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of valsartan following oral administration is approximately 4.5 l/h. Age does not affect the apparent clearance in heart failure patients.</p><p><em><u>Special populations</u></em></p><p><u>Older people</u></p><p>A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.</p><p><u>Impaired renal function</u></p><p>As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan. Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance &gt;10 ml/min). There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 4.4). Valsartan is highly bound to plasma protein and is unlikely to be removed by dialysis.</p><p><u>Hepatic impairment</u></p><p>Approximately 70% of the dose absorbed is eliminated in the bile, essentially in the unchanged form. Valsartan does not undergo any noteworthy biotransformation. A doubling of exposure (AUC) was observed in patients with mild to moderate hepatic impairment compared to healthy subjects. However, no correlation was observed between plasma valsartan concentration versus degree of hepatic dysfunction. Valsartan has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).</p><p><em><u>Paediatric population</u></em></p><p>In a study of 26 paediatric hypertensive patients (aged 1 to 16 years) given a single dose of a suspension of valsartan (mean: 0.9 to 2 mg/kg, with a maximum dose of 80 mg), the clearance</p><p>(litres/h/kg) of valsartan was comparable across the age range of 1 to 16 years and similar to that of adults receiving the same formulation (see Absorption information under section 5.2).</p><p><u>Impaired renal function</u></p><p>Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.</p><p>In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.</p><p>Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p><em><u>Paediatric population</u></em></p><p>Daily oral dosing of neonatal/juvenile rats (from a postnatal day 7 to postnatal day 70) with valsartan at doses as low as 1 mg/kg/day (about 10-35% of the maximum recommended paediatric dose of 4 mg/kg/day on systemic exposure basis) produced persistent, irreversible kidney damage. These effects above mentioned represent an expected exaggerated pharmacological effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 blockers; such effects are observed if rats are treated during the first 13 days of life. This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans. The rats in the juvenile valsartan study were dosed up to day 70, and effects on renal maturation (postnatal 4-6 weeks) cannot be excluded. Functional renal maturation is an ongoing process within the first year of life in humans. Consequently, a clinical relevance in children &lt;1 year of age cannot be excluded, while preclinical data do not indicate a safety concern for children older than 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, croscarmellose sodium, povidone K30, anhydrous colloidal silica, magnesium stearate, Opadry II White (lactose monohydrate, HPMC, titanium dioxide, macrogol), FD&amp;C red #40.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Avysk<sup>&reg;</sup> 80 mg tablets</strong>: are pink color round biconvex film coated tablets engraved with H27 on one side and scored on the other side, presented in Alu/Alu blisters, intended for oral use.</p><p>The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.</p><p><strong>Pack size</strong>: 30 film coated tablets (10 film coated tablets/blister, 3 blisters/pack).</p><p><strong>Avysk<sup>&reg;</sup> 160 mg tablets</strong>: are pink color round biconvex film coated tablets engraved with H25 on one side and plain on the other side, presented in Alu/Alu blister, intended for oral use.</p><p><strong>Pack size</strong>: 30 film coated tablets (10 tablets/blister, 3 blisters/pack).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma-KSA.
1st Industrial city, Phase 5, Jeddah –KSA.
Tel: 00966920003288
Mobile: 00966555786968
P.O .Box: 4072 - Jeddah 22429
E-mail:  info@medcitypharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>